Building Success in China’s Pharma Sector
The Chinese pharmaceutical sector growth slowed further in 2015 to around 10% under the shadow of
numerous challenges mostly stemmed from the troubled Chinese economy, regulatory shakeups, cost
containment measures and healthcare reform turbulences.
There is no doubt the healthcare reform will go on with unchanged ambitions. In the reality, with tax and
other revenues drying up and under increasing threat of BMI system deficit amid a slowing Chinese
economy, local governments are pressured by both the central government and the public to do more
with less. Despite its superficial goals, the healthcare reform has so far mostly been hijacked by
containment of drug costs and no longer about improving efficiency and fixing structural flaws.
Pushed to the corner, both domestic and multinational drug companies are now at the brink of business
bottomlines. However, the trend of irrational cost containment is expected to intensify further in 2016,
with the central goverment upholding the radical healthcare reform experiment in Sanming City of Fujian
Province as a model for national reference.
The pharma e-commerce sector has been brewing major revolutionary developments pending official
liberalization of online prescription drug sales. Under growing pressure from aggressive moves by
e-commerce giants to enter drug distribution, leading pharmaceutical distributors rushed to reposition
themselves to secure presence in the emerging pharma e-commerce sector in China.
In the meantime, the recent CFDA's move to elevate drug quality and reform drug approval system,
though contradicted by other government agency's preoccupation to slash drug costs, provides a ray of
future hope for MNCs. With a better policed pharmaceutical industry aligned to rational cost structures,
MNCs can expect to compete with domestic companies on a more leveled ground in future and fill
market vacuum from exiting irregular players. The real questions are that, with the world's largest
population, what kind of healthcare solution and product mix China can and should get for merely
5%-6% of GDP? Is the country willing or able to pay more for better drugs and healthcare?
The Chinese economy and its healthcare system are at crossroads and in transition again. This
requires both domestic and MNC pharma companies to recalibrate their strategies and business models.
Many drug company executives are still bullish about China's long-term growth prospects and drug
spending is expected by IMS to reach as much as US $185 billion by 2018. But the short-term picture is
proving less rosy, with reforms in the hospital sector impacting prescribing and price pressures
increasing for most drugs.
Chinese experts warned recently that the pharmaceutical industry is facing a more complex Chinese
marketplace in 2016. There will be lots of uncertainties, unbalances and frailty ahead. The future
outlook is mixed, while most analysts agree that the market will keep on growing, but at a slower rate,
continuing the trend which started two years ago.
Other than growing challenges on the ground in China, there are success stories from all categories of
players, whether they are foreign or local, large or small, newcomer or established, private or state-
owned. However, to be one of the success stories requires a thorough understanding of the sector,
ability to face and tackle challenges, flexibility to deal with changes and skills to maneuver through
To cater for the growing needs of headquarter pharmaceutical executives for better understanding of
the Chinese market, the Seminar was launched in 2009 by Pharma China, the most trusted English
media and source of business intelligence covering the Chinese pharmaceutical / biopharmaceutical
industry and market.
“Pharma China Seminar - Building Success in China’s Pharma Sector” is a one-day
seminar providing insights into contemporary trends/issues and the most important aspects of the
Chinese pharmaceutical industry and marketplace today. This year's event will focus on healthcare
policies, drug regulations, market access and strategic issues as well as potential impacts of latest and
upcoming policy changes on the Chinese pharma industry. In addition, contemporary trends of M&A's,
R&D and licensing, business hotspots and e-commerce, as well as future market outlook will be explored.
On the basis of our successful experience with the event in the past five years, Pharma China Seminar
2016 will refocus its agenda to provide more in-depth coverage of and strategic insights into the
following key aspects of Chinese pharma business including 1) latest trends and issues in drug
regulation and healthcare policies, 2) impacts of deepening healthcare reform on the pharma industry
and changing business models; 3) changing dynamics in Chinese pharma and evolving new business
model, 4) changing role of China in global supply chain of pharma companies; 5) R&D, partnership and
licensing trends & strategies; 6) dynamic healthcare and disease trends, 7) licensing, business hotspots
and e-commerce 8) emerging IP/legal/compliance issues, 9) new opportunity areas such as biosimilars,
and 10) pharma/healthcare market outlook.
At least ten leading experts of the Chinese pharmaceutical/healthcare sector with different specialization
will share their expertise and knowledge through exclusive data, detailed analysis, case studies and
interactive panel discussions.
Who should attend?
- Senior executives
- Strategic planning/business development/CI/market research executives
- Executives responsible for outsourcing
- R&D/licensing/regulatory executives
- Regional HQ executives
- Expatriate executives in China
- CRO executives
- Investment/VC professionals
Why should you attend?
- Learn about the present state and future outlook of the Chinese pharma industry and marketplace
- Identify emerging opportunity areas and growth drivers
- Examine major intellectual property issues and legal risks
- Stay informed for the latest developments in Chinese drug regulation and healthcare policy
- Gain insights into key aspects of Chinese pharma business
- Brainstorm successful China business strategies
What does the seminar cover?
- Contemporary trends, issues and challenges
- Future growth drivers, opportunities and outlook
- Healthcare reform and impacts on pharma sector
- Intellectual property/patent-related issues
- Pricing and reimbursement/health insurance system
- Pharmaceutical marketing and distribution channel strategies
- Regulatory process for new drug development and registration
- Considerations for developing successful China business strategies
- Rising global importance of China – sourcing and licensing opportunities
About Pharma China
Pharma China (www.pharmachinaonline.com) is the most influential English media and source of
business intelligence covering the Chinese pharmaceutical / biopharmaceutical industry and market.
Pharma China caters for the growing needs of the international pharmaceutical industry for up-to-date
and insightful intelligence on China’s burgeoning but increasingly complex healthcare marketplace. It is
subscribed by most multinational pharmaceutical companies, leading CROs, investment banks,
consulting firms and industry associations.
Pharma China publishes the following products:
- Pharma China Journal Edition (monthly in PDF and Print)
- Pharma China Web Edition (continuously-updated news and in-depth commentaries)
- China Pharmaceutical Guide (the most comprehensive and authoritative reference for China’s
- The above are available as standalone products or two value packages